Literature DB >> 25774942

Interleukin-21 inhibits HBV replication in vitro.

Hai-Jun Li1, Fu-Biao Kang, Bao-Sheng Li, Xin-Ying Yang, Yin-Ge Zhang, Dian-Xing Sun.   

Abstract

BACKGROUND: Cytokines are crucial factors in the non-cytolytic antiviral process to inhibit HBV gene expression and replication. Interleukin (IL)-21 has been suggested to play an important role in HBV infection, but it remains unknown whether IL-21 can inhibit HBV replication or how it inhibits HBV replication.
METHODS: In this study, we investigated the influence of IL-21 on HBV replication based on human hepatoma Huh7.93 cells co-cultured with human peripheral blood mononuclear cells (PBMCs) and the possible correlation among IL-21, interferon-γ, tumour necrosis factor-α and IL-10.
RESULTS: We demonstrated that the decrease of IL-21 expression and the increase of IL-10 expression in PBMCs could promote HBV replication in vitro. We further revealed that IL-21 is not only able to effectively suppress HBV replication directly but also reduce HBV replication by inhibition of IL-10 secretion.
CONCLUSIONS: Our results provide important evidence for the non-cytolytic antiviral mechanism mediated by cytokines and their interactions in chronic hepatitis B.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25774942     DOI: 10.3851/IMP2950

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  5 in total

1.  [A recombinant adenovirus vector carrying murine interleukin-21 gene controls chronic HBV infection in mice].

Authors:  Xue-Ping Gao; Yang Zhou; Xin-Chun Zheng; Xuan Yi; Li-Bo Tang; Jin-Lin Hou; Yong-Yin Li
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-11-20

Review 2.  Crosstalk between innate and adaptive immunity in hepatitis B virus infection.

Authors:  Li Wang; Kai Wang; Zhi-Qiang Zou
Journal:  World J Hepatol       Date:  2015-12-28

3.  IL-21 Is Associated With Virological Relapse of HBeAg Positive Chronic Hepatitis B After Discontinuance of Entecavir.

Authors:  Lihua Huang; Li Zhou; Jianhe Gan; Wenlong Yang; Yaping Dai; Tingting Su; Yuanwang Qiu
Journal:  Turk J Gastroenterol       Date:  2021-02       Impact factor: 1.852

4.  Serum IL-21 levels predict HBeAg decline during rescue therapy in patients with partial response to nucleos(t)ide analogues.

Authors:  Yue Li; Calvin Q Pan; Shibo Ji; Gaiqin Yan; Jun Cheng; Shunai Liu; Huichun Xing
Journal:  Exp Ther Med       Date:  2021-01-15       Impact factor: 2.447

5.  Hepatitis B Virus-Specific Cellular Immunity Contributes to the Outcome of Occult Hepatitis B Virus Infection.

Authors:  Weiyun Zhang; Shengxue Luo; Tingting Li; Min Wang; Jieting Huang; Qiao Liao; Bochao Liu; Xia Rong; Linhai Li; Jean-Pierre Allain; Yongshui Fu; Chengyao Li
Journal:  Front Microbiol       Date:  2022-04-07       Impact factor: 5.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.